Pharma stock jumps 6% after receiving approval to list its associate company on BSE & NSE

Published 23-01-2025, 01:43 pm
© Reuters.  Pharma stock jumps 6% after receiving approval to list its associate company on BSE & NSE

This Smallcap Pharma Shares which deals in the business of generic formulations manufacturing in different dosage forms surged 6 percent after its associate OneSource received approval from BSE & NSE for listing.

Share Price Movement

In Thursday’s trading session, the share price of Strides Pharma Science (NSE:SRID) touched a day’s high of Rs. 627 per share which was up by 7.79 percent. The stock reiterated from the day’s high and was trading at Rs. 620.45 per share which is 6.67 percent higher than the previous closing price of Rs. 581.65 per share.

Take advantage of AI-Powered ProPicks, Advanced Stock Screener, Fair Value, Financial Health, etc., with InvestingPro and take advantage of our New Year's Sale offer to stay ahead.

What happened

The company’s stock surged after the company got approval for listing its associate company which is India’s first Specialty Pharma CDMO named OneSource from BSE and NSE. The company received approval on Wednesday, January 22, 2025, and as per filing the OneSource company is to get listed under the Scrip Code for NSE: ONESOURCE and BSE:544292. It will be listed on bourses dated 24th January 2025, Friday on NSE and BSE.

De-merger

Strides Pharma Science had received approval from the National Company Law Tribunal of demerger the Identified CDMO business of Strides and Soft Gelatin Business and Steriscience into OneSource company. They had a fixed record date on 06th December 2024 and shareholders were to receive 30 fully paid equity shares in OneSource for every 60 shares of Strides Pharma.

Guidance

The company said that they are committed to achieve $400 Million revenue target from the US Business in the upcoming two to two and half years.

Financials

In its Q2FY25 financial results, Strides Pharma reported revenue of Rs.1,201 crore, a 20.22 percent increase from Rs.999 crore in the same quarter of the previous year. The Profit After Tax from a loss of Rs. 149 crore in Q2FY24 to a profit of Rs.94 crore in Q2FY25.

Company Profile

Strides Pharma Science Ltd is headquartered in India. They specialize in developing and manufacturing niche generic pharmaceuticals. The company focuses on regulated markets and has a diverse portfolio of over 65 products.

Written by – Santhosh S

Disclaimer

The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Pharma stock jumps 6% after receiving approval to list its associate company on BSE & NSE appeared first on Trade Brains.

Read More

To understand more about InvestingPro, watch this video: https://www.youtube.com/watch?v=_WfQcN5vjI

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.